Hypoglycemia has not been associated with the use of Targretin capsules as monotherapy. Retinoids as a class have been associated with photosensitivity. In vitro assays indicate that bexarotene is a potential photosensitizing agent. Laboratory Tests Blood lipid determinations should be performed before Targretin capsules are given. Fasting triglycerides should be normal or normalized with appropriate intervention prior to therapy.
Hyperlipidemia usually occurs within the initial two to four weeks.
Therefore, weekly lipid determinations are recommended during this interval. A white blood cell count with differential should be obtained at baseline and periodically during treatment. Baseline liver function tests should be obtained and should be carefully monitored after one, two and four weeks of treatment initiation, and if stable, periodically thereafter during treatment. In all clinical trials, patients were instructed to take Targretin capsules with or immediately following a meal. In one clinical study, plasma bexarotene AUC and C max values were substantially higher following a fat-containing meal versus those following the administration of a glucose solution.